Related Experiment Videos
Antihypertensive therapy and the concept of total cardiovascular protection
1Western Heart Institute, St. Mary's Hospital and Medical Center, San Francisco, California 94117.
Insights
Treating mild hypertension with beta blockers, like acebutolol, and thiazide diuretics can significantly lower cardiovascular risks. This approach is effective for managing hypertension and improving patient longevity.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Elevated blood pressure (hypertension) increases cardiovascular mortality and morbidity.
- Studies demonstrate antihypertensive drug benefits in mild hypertension, including stroke prevention and improved longevity.
- The Hypertension Detection and Follow-up Program trial showed reduced coronary events in mild hypertensive patients.
Purpose of the Study:
- To evaluate the benefits of antihypertensive drug therapy in patients with mild hypertension.
- To propose a practical, modified stepped-care regimen for widespread hypertension management.
- To identify an optimal beta blocker for initial hypertension treatment.
Main Methods:
- Review of existing antihypertensive drug studies in mild hypertensive subjects.
- Analysis of the Hypertension Detection and Follow-up Program trial data.
- Evaluation of pharmacologic properties of available beta blockers for hypertension management.
Main Results:
- Antihypertensive therapy in mild hypertension offers protection against stroke, left ventricular hypertrophy, heart failure, and renal damage.
- Drug treatment in mild hypertension is associated with improved patient longevity and reduced coronary artery disease events.
- Acebutolol exhibits favorable properties (cardioselectivity, intrinsic sympathomimetic activity, hydrophilicity) for initial hypertension management.
Conclusions:
- A modified stepped-care regimen with initial beta blocker therapy and optional thiazide diuretic is a judicious approach for essential hypertension.
- Acebutolol is identified as an effective and safe beta-blocking agent for first-line management of a broad hypertensive population.
- Effective hypertension management, even in mild cases, is crucial for reducing cardiovascular risks and improving long-term health outcomes.
Abstract:
Drug-induced reduction of elevated blood pressure decreases cardiovascular mortality and morbidity in patients with moderate and severe hypertension. Furthermore, antihypertensive drug studies in mild hypertensive subjects (diastolic blood pressure 90 to 104 mm Hg) have shown protection against stroke, left ventricular hypertrophy, congestive heart failure and progression of renal damage, as well as improved patient longevity. The Hypertension Detection and Follow-up Program trial, recently carried out in the U.S., documented reduced coronary artery disease events (fatal and nonfatal) in special drug-treated patients with mild hypertension. From the standpoint of practical management and considering the ubiquity of essential hypertension, a modified stepped-care regimen advocating initial drug therapy with a beta blocker and addition of low-dose thiazide diuretic when necessary constitutes a judicious approach for widespread application. Although there are 8 orally active beta blockers currently approved in the U.S. for clinical use in systemic hypertension, only acebutolol possesses all of the salutary pharmacologic properties of cardioselectivity, intrinsic sympathomimetic activity and hydrophilicity, thereby making this compound an effective and safe beta-blocking agent for first-order management of a broad segment of the hypertensive population.